Global mRNA Vaccine and Therapeutics Market Zooming 2.7X to Cross USD 36 Billion by 2031

Published | 07 July 2025

Global mRNA Vaccine and Therapeutics Market is flourishing because of an escalating demand for gene and cell therapies, an increasing number of regulatory approvals for viral vector-based drugs and vaccines, and the rising volume of clinical trials in the innovative therapeutic space.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global mRNA Vaccine and Therapeutics Market size at USD 13.36 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Global mRNA Vaccine and Therapeutics Market size to boom at a robust CAGR of 15.5% reaching a value of USD 36.64 Billion by 2031. The growth of mRNA Vaccine and Therapeutics Market across the regions is propelled by an increasing focus on mRNA-based treatments for chronic diseases. These lab-generated therapeutics offer enhanced safety, production efficiency, and superior immunological advantages over traditional DNA vaccines by triggering robust B- and T-cell immune responses through viral antigen production. The urgent global demand for effective COVID-19 vaccines greatly accelerated mRNA research and development, prompting pharmaceutical companies to prioritize these solutions. Furthermore, the emergence of new viral strains has led regulatory authorities to fast-track approvals via emergency and conditional authorizations, further fueling market expansion.

Impact of Escalating Geopolitical Tensions on Global mRNA Vaccine and Therapeutics Market

Intensifying geopolitical tensions could disrupt the growth of Global mRNA Vaccine and Therapeutics Market. Such conflicts invariably disrupt global supply chains, jeopardizing the timely availability of crucial raw materials and specialized components essential for mRNA vaccine production. Trade restrictions, sanctions, and border closures can lead to considerable delays in manufacturing timelines and drive up production costs, impacting affordability and accessibility. Furthermore, political instability often results in a reallocation of government funding, potentially diverting resources away from vital healthcare innovation, thereby impeding research and development efforts in the mRNA space. The inherent uncertainty in international relations can also hinder global collaborations and regulatory harmonization, both of which are critical for the efficient conduct of clinical trials and the equitable distribution of these life-saving therapeutics. Collectively, these multifaceted challenges present substantial risks to the market's anticipated expansion and global accessibility.

Sample Request: https://www.blueweaveconsulting.com/report/mrna-vaccine-and-therapeutics-market/report-sample

North America Leads Global mRNA Vaccine and Therapeutics Market

North America currently holds and is expected to maintain the largest share in the Global mRNA Vaccine and Therapeutics Market. The dominance is largely driven by strong contributions from United States and Canada, with United States at the forefront due to substantial funding for mRNA vaccine development, a robust pipeline of therapeutic candidates, and the significant presence of both established and emerging pharmaceutical companies. The region benefits from advanced manufacturing infrastructure, including sophisticated ultracold supply chains, and increasing public awareness of mRNA technologies. Key industry players like Moderna and strategic partnerships, such as with Catalent for large-scale production, have further solidified the regional market. Additionally, investments from organizations like CEPI and active involvement of companies such as Translate Bio and Arcturus Therapeutics are fueling continued growth, ensuring North America's sustained leadership in the Global mRNA Vaccine and Therapeutics Market.

Competitive Landscape

Major companies in Global mRNA Vaccine and Therapeutics Market include Sanofi, GSK Plc., AstraZeneca, CureVac N.V., Moderna Inc., Arcturus Therapeutics, BioNTech SE, Pfizer Inc., Daiichi Sankyo Company, Silence Therapeutics, Ethris GmbH, Panthera Therapeutics GmbH, Argos Therapeutics Inc., Gennova Biopharmaceuticals Ltd, and Providence Therapeutics. The presence of high number of companies intensify the market competition as they compete to gain a significant market share. These companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches to further enhance their market share.

Don’t miss the business opportunity in Global mRNA Vaccine and Therapeutics Market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global mRNA Vaccine and Therapeutics Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global mRNA Vaccine and Therapeutics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Scope of the Report

About Us

BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing qualitative and quantitative data to boost the performance of your business solutions. BlueWeave has built its reputation by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.

Contact Us:

BlueWeave Consulting & Research Pvt Ltd

+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662

info@blueweaveconsulting.com